Soleno Therapeutics (SLNO) Soars 32% on $2.9-Billion Merger

Soleno Therapeutics Inc. (NASDAQ:SLNO) is one of the 10 Stocks With Unexpected Gains.

Soleno Therapeutics soared by 32.31 percent on Monday to close at $52.25 apiece, as investors gobbled up shares following news that it is set to be acquired by Neurocrine Biosciences Inc. at a 34-percent upside.

In a statement, Neurocrine said that it entered into a definitive agreement with Soleno Therapeutics Inc. (NASDAQ:SLNO) for the acquisition of all its issued and outstanding shares at a price of $53 apiece, for a total of $2.9 billion.

Prior to the announcement, Soleno Therapeutics Inc. (NASDAQ:SLNO) last traded at $39.49.

The merger is set to expand Neurocrine’s portfolio of innovative medicines, with the addition of VYKAT XR, and strengthen its leadership position in endocrinology and rare disease.

Since securing the approval of the Food and Drug Administration last year, VYKAT XR has already generated $190 million in 2025 revenues for Soleno Therapeutics Inc. (NASDAQ:SLNO), of which $92 million was registered in the fourth quarter alone.

“Neurocrine is the right strategic partner to expand the reach of VYKAT XR in the Prader-Willi syndrome community, given their experience in endocrinology and rare disease and their proven ability to execute successful commercial launches. We are excited to accelerate VYKAT XR’s impact for PWS patients following completion of the transaction by leveraging Neurocrine’s strong commercial capabilities,” said Soleno Therapeutics Inc. (NASDAQ:SLNO) Chairman and Chief Executive Officer Anish Bhatnagar.

While we acknowledge the risk and potential of SLNO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SLNO and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.